GENERALIZED PUSTULAR PSORIASIS
Clinical trials for GENERALIZED PUSTULAR PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new GENERALIZED PUSTULAR PSORIASIS trials appear
Sign up with your email to follow new studies for GENERALIZED PUSTULAR PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Five-Year trial tests drug for severe skin disease flares
Disease control OngoingThis study is testing the long-term safety and effectiveness of the drug spesolimab for people with generalized pustular psoriasis (GPP), a serious skin condition. Participants who previously took spesolimab in earlier trials receive the drug for nearly five years to see how well…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug trial targets rare, severe skin disease
Disease control OngoingThis study is testing an experimental medication called JNJ-77242113 for people with two severe forms of psoriasis: generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). The main goal is to see how well the drug improves skin symptoms and overall condition over 1…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New treatment tested for severe, recurring skin disease flares
Disease control OngoingThis study is testing a medication called spesolimab for adults who experience repeated, severe flare-ups of generalized pustular psoriasis (GPP), a serious skin condition. Participants receive spesolimab as an intravenous infusion at the start of a flare and may receive a second…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE4 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug trial targets severe, painful skin disease
Disease control OngoingThis study is testing an investigational drug called TAK-279 in adults with two severe and rare forms of psoriasis: generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). All participants will receive the drug for up to 52 weeks. The main goal is to see how well i…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC